• Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments | Morningstar

    来源: Buzz FX / 08 11月 2024 08:31:27   America/New_York


    Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Ac
    Read more...
分享